Skip to main content
Top

29-01-2025 | Testosterone | Original Research Article

Leveraging Model-Based Simulations to Optimize Extended Dosing of Leuprolide 6-Month Intramuscular Depot Formulation

Author: Li-Feng Hsu

Published in: European Journal of Drug Metabolism and Pharmacokinetics

Login to get access

Abstract

Background and Objective

A gonadotropin-releasing hormone (GnRH) agonist such as leuprolide is widely used to achieve sustained suppression of testosterone levels, which play a critical role in the treatment of prostate cancer. Recent advances in drug delivery systems have led to the development of long-acting depot formulations, such as the 6-month intramuscular (IM) leuprolide formulation, which aim to simplify dosing and improve convenience for both patients and healthcare providers. Exploring extended dosing intervals for such formulations represents a promising approach to further optimize treatment regimens, potentially balancing efficacy with patient-centered care. The objective was to evaluate the efficacy of various extended dosing regimens of the leuprolide 6-month IM depot formulation for prostate cancer treatment. The primary objective was to assess whether extended dosing intervals could maintain testosterone concentrations below the castrate threshold of < 0.5 ng/ml and < 0.2 ng/ml in over 90% of subjects, as outlined in regulatory criteria.

Methods

The study utilized a previously published pharmacokinetic/pharmacodynamic model to simulate the testosterone suppression profiles for different extended dosing regimens, including every 6 months (Q6M), 7 months (Q7M), 8 months (Q8M), 9 months (Q9M), 10 months (Q10M), 11 months (Q11M), and 12 months (Q12M). The simulations were carried out with 1000 virtual subjects. Sensitivity analyses were also conducted to account for variability in baseline testosterone levels and fraction of drug absorbed.

Results

The simulation results indicated that extending the dosing interval from Q6M to Q8M could ensure that over 90% of subjects maintain testosterone concentrations below 0.2 ng/ml. Similarly, extending the dosing interval to Q9M would keep testosterone concentrations below 0.5 ng/ml in over 90% of subjects. The sensitivity analyses confirmed that these extended dosing regimens consistently achieved and maintained target testosterone levels across various scenarios.

Conclusion

The findings support the feasibility of extending the dosing intervals for the leuprolide 6-month IM depot formulation beyond the label-recommended 6 months. Specifically, the Q8M and Q9M regimens emerged as viable candidates for further clinical evaluation, offering potential benefits in reducing injection frequency while maintaining therapeutic efficacy. Further clinical studies are necessary to confirm the long-term efficacy of these extended dosing regimens.
Literature
6.
go back to reference Schulman C, Cornel E, Matveev V, Tammela TL, Schraml J, Bensadoun H, Warnack W, Persad R, Salagierski M, Gómez Veiga F, Baskin-Bey E, López B, Tombal B. Intermittent versus continuous androgen deprivation therapy in patients with relapsing or locally advanced prostate cancer: a phase 3b randomised study(ICELAND). Eur Urol. 2016;69(4):720–7. https://doi.org/10.1016/j.eururo.2015.10.007.CrossRefPubMed Schulman C, Cornel E, Matveev V, Tammela TL, Schraml J, Bensadoun H, Warnack W, Persad R, Salagierski M, Gómez Veiga F, Baskin-Bey E, López B, Tombal B. Intermittent versus continuous androgen deprivation therapy in patients with relapsing or locally advanced prostate cancer: a phase 3b randomised study(ICELAND). Eur Urol. 2016;69(4):720–7. https://​doi.​org/​10.​1016/​j.​eururo.​2015.​10.​007.CrossRefPubMed
7.
go back to reference Ortiz M. Benefits of less frequent injections in advanced prostate cancer. Aust Fam Physician. 2015;44(6):429–30.PubMed Ortiz M. Benefits of less frequent injections in advanced prostate cancer. Aust Fam Physician. 2015;44(6):429–30.PubMed
13.
go back to reference Spitz A, Gittelman M, Karsh LI, Dragnic S, Soliman AM, Lele A, Gruca D, Norton M. Intramuscular depot formulations of leuprolide acetate suppress testosterone levels below a 20 ng/dL threshold: a retrospective analysis of two Phase III studies. Res Reports Urol. 2016;8:159–64. https://doi.org/10.2147/rru.S111475.CrossRef Spitz A, Gittelman M, Karsh LI, Dragnic S, Soliman AM, Lele A, Gruca D, Norton M. Intramuscular depot formulations of leuprolide acetate suppress testosterone levels below a 20 ng/dL threshold: a retrospective analysis of two Phase III studies. Res Reports Urol. 2016;8:159–64. https://​doi.​org/​10.​2147/​rru.​S111475.CrossRef
16.
go back to reference Maluf FC, Schutz FA, Cronemberger EH, Luz MA, Martins SPS, Muniz DQB, Bastos DA, Cárcano FM, Smaletz O, Soares A, Peixoto FA, Gomes AJ, Cruz FM, Franke FA, Herchenhorn D, Dos Santos TM, Fabricio VC, Gidekel R, Werutsky G, de Jesus RG, et al. A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415). Eur J Cancer (Oxford, England: 1990). 2021;158:63–71. https://doi.org/10.1016/j.ejca.2021.08.032. (Advance online publication).CrossRef Maluf FC, Schutz FA, Cronemberger EH, Luz MA, Martins SPS, Muniz DQB, Bastos DA, Cárcano FM, Smaletz O, Soares A, Peixoto FA, Gomes AJ, Cruz FM, Franke FA, Herchenhorn D, Dos Santos TM, Fabricio VC, Gidekel R, Werutsky G, de Jesus RG, et al. A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415). Eur J Cancer (Oxford, England: 1990). 2021;158:63–71. https://​doi.​org/​10.​1016/​j.​ejca.​2021.​08.​032. (Advance online publication).CrossRef
Metadata
Title
Leveraging Model-Based Simulations to Optimize Extended Dosing of Leuprolide 6-Month Intramuscular Depot Formulation
Author
Li-Feng Hsu
Publication date
29-01-2025
Publisher
Springer International Publishing
Published in
European Journal of Drug Metabolism and Pharmacokinetics
Print ISSN: 0378-7966
Electronic ISSN: 2107-0180
DOI
https://doi.org/10.1007/s13318-024-00932-1